Pharmacokinetics and safety of ticagrelor in infants and toddlers with sickle cell disease aged <24 months. Issue 5 (25th February 2021)

• Record Type: Journal Article
• Authors: Duniva Inusa, Baba Psalm; Inati, Adlette; Maes, Philip; Githanga, Jessie; Ogutu, Bernhards; Abboud, Miguel R.; Miano, Maurizio; Cela, Elena; Nduba, Videlis; Niazi, Mohammad; Åstrand, Magnus; Persson, Kevin; Berggren, Anders; Carlson, Glenn
• Is Part Of: Pediatric blood & cancer. Volume 68:Issue 5(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-02-25
• Subjects: paediatric -- pharmacokinetic -- sickle cell disease -- ticagrelor; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.28977
• Languages: English
• ISSNs: 1545-5009

Abstract

Abstract: Inhibition of platelet activation may reduce vaso‐occlusion rates in patients with sickle cell disease (SCD). In the HESTIA4 (NCT03492931) study, 21 children with SCD received a single oral dose of the antiplatelet agent ticagrelor (0.1 mg/kg <6 months; 0.2 mg/kg ≥6 to <24 months). All patients had measurable ticagrelor plasma concentrations. Ticagrelor and active metabolite (AR‐C124910XX) exposure were comparable across all groups (<6 months, ≥6 to <12 months and ≥12 to <24 months). Ticagrelor was well tolerated. Palatability was generally acceptable. These data will be used to enable dose selection for further investigations of ticagrelor efficacy and safety in children with SCD.